A model for cancer chemo-immunotherapy treatment schedules

This work constructs a generic model for chemo-immunotherapy of cancer in a healthy tissue. The main interests are the modeling and computer study of chemotherapy, immunotherapy and the advantages in their combined applications. It describes the dynamics of Healthy, Immune, and Cancer cells when chemotherapy and immunotherapy are applied, either separately or combined. The analysis of the model shows that its solutions exist, are bounded and nonnegative on each finite time interval, and thus are biologically feasible. The model simulations describe the development of the disease without intervention, when only chemotherapy or immunotherapy are administered periodically, when the two modalities are combined. In this manner, once validated, the model can be used to design treatment schedules for improved outcomes.

Authors

Institutions

Publication Details

Journal
BIOMATH
Published
2025-05-22
DOI
https://doi.org/10.55630/j.biomath.2025.05.225
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A model for cancer chemo-immunotherapy treatment schedules

Tilak Dutta, Meir Shillor, J. M. Moore, Silmera A. Sangma
BIOMATH
Cancer Immunotherapy and Biomarkers
article

A model for cancer chemo-immunotherapy treatment schedules

Tilak Dutta, Meir Shillor, J. M. Moore, Silmera A. Sangma
article en

Abstract

This work constructs a generic model for chemo-immunotherapy of cancer in a healthy tissue. The main interests are the modeling and computer study of chemotherapy, immunotherapy and the advantages in their combined applications. It describes the dynamics of Healthy, Immune, and Cancer cells when chemotherapy and immunotherapy are applied, either separately or combined. The analysis of the model shows that its solutions exist, are bounded and nonnegative on each finite time interval, and thus are biologically feasible. The model simulations describe the development of the disease without intervention, when only chemotherapy or immunotherapy are administered periodically, when the two modalities are combined. In this manner, once validated, the model can be used to design treatment schedules for improved outcomes.

BIOMATHVol. 14(1)
Assam Don Bosco University (IN), Oakland University (US)
Openalex Percentile: Top 83%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A model for cancer chemo-immunotherapy treatment schedules — Tilak Dutta, Meir Shillor, et al. · BIOMATH (2025) | TGRS Research Map | TGRS